The exact mechanism of HIV infection of CD4+ T cells

[1]Cooley LA, Lewin SR 。 HIV-1 cell entry and advances in viral entry inhibitor therapy[J] 。 J Clin Virol , 2003, (26): 121。[2]Goto T, Nakai M, Ikuta K。 The life-cycle of human immunodeficiecy virus type 1[J]。 Micron,1998,29(2/3):123。[3]王颖,王晓峰,傅学奇。HIV-1复制抑制剂的新靶标[J]。生命的化学,2001,21(6):485。[4]魏文青,王明霞。抗病毒药物的分子靶标[J]。国外医学·药学分册,2001,28(5):266。[5]Jacobson JM, Lowy I, Fletcher CV, et al。 Single-dose safety,phacmacology, and antiviral activity of the human immunodeficiecy virus (HIV) type 1 entry inhibitor PRO542 in HIV-infected adults[J]。 J Infect Dis ,2000,182(1) :326。[6]Shearer WT, Israel RT, Starr S, et al。 Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2study[J]。 J Infect Dis ,2000,182(6): 1774。[7]Esser M, Mori T, Mondor I, et al。 Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding,fusion,and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120[J]。 J Virol ,1999 , 73 : 4360 。[8]Wyatt R, Kwong P, Desjardins E, et al。 The antigenic structure of the HIV gp120 envelope glucoprotein[J]。 Nature, 1998,393:705。[9]徐志凯,姜世勃。针对HIV-1进入细胞过程的抑制剂研究进展[J]。细胞与分子免疫学杂志,2001,17(5):401。[10]Hoshino H。 Coreceptors of H1V infection and the development of HIV entry inhibitors: overview and targets[J]。 Jpn J Clin Med, 2002,60(1):81。[11]Berson J F, Doms R W。 Structure-function studies of the HIV-1 coreceptors[J]。 Semin Immunol , 1998,10:237。[12]Bleul C, Farzan M, Choe H, et al。 The lymphocyte chemoattractant SDF-1 is a ligand for LESTER/fusin and blocks HIV-1 entry[J]。 Nature, 1996,382: 829。[13]Deng H, Liu RH, Ellmeier W, et al。 Identification of a majorco-receptor for primary isolates of HIV-1[J]。 Nature, 1996,381:661。[14]张应玖,金宁一,殷震,等。HIV的致病机制研究进展[J]。微生物学杂志,2000,20(1):42。[15]Zaitseva M, Peden K, Golding H。 HIV coreceptors:role of structure, posttranslational modifications, and intemalization in viral-cell fusion and as targets for entry inhibitors [J]。 Biochim Biophys Acta, 2003,1614:51。[16]Speck RF, Wehrly K, Platt EJ, et al。 Selective employment of chemokine receptors as human immunodeficiecy virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop [J]。 J Viral, 1997,71:7136。[17]Sabbe R, Picchio GR, Pastore C, et al。 Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression[J]。 J Virol,2001,75(2) :661。[18]Tamamura H, Omagari A, Oishi S。 Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective antiHIV agents with very high selectivity indexes[J]。 Bioorg Med Chem Lett ,2000,10(23) :2633。[19]Dirk D, Dominique S, Myriam W, et al。 A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibitor of human immunodeficiecy virus replication by blocking CXCR4-mediated virus entry[J]。 Mol Pharmacol, 2000, 57(1): 116。[20]董肖椿,闻韧。作用于趋化因子受体的新型抗HIV药物研究进展[J]。药学学报,2001,36(10):796。[21]de Clercq E。 New developments in anti-HIV chemotherapy[J]。 Biochim Biophys Acta ,2002,1587:258。[22]EsteJ, CabreraC, BlancoJ, etal。 Shift of clinical human immunodeficiecy virus type 1 isolates from X4 to R5 and prevention of the formarion of syncytium-inducing phenotype by blockade of CXCR4[J]。 J Virol , 1999,73: 5577。[23]O'Hara BM, Olson WC。 HIV entry inhibitors in clinical development [J]。 Curr Opin Pharmcol, 2002, 2(5):523。[24]Lynch CL, Hale JJ, Budhu RJ, et al。 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists。 Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV[J]。 Bioorg Med Chem Lett , 2002,12:3001。[25]Labranche CC, Galasso G, Moore JP, et al。 HIV fusion and its inhibition[J]。 Antiviral Res,2001,50: 95。[26]O'Brien SJ,Moore JP。 The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS[J]。Immunol Rev ,2000,177:99。[27]Jiang S, Zhao Q, Debnath AK。 Peptide and non-peptide HIV fusion inhibitors [J]。 Curr Pharm Des, 2002,8 (8): 563。[28]邱阳。HIV-1进攻靶细胞的机制及相应环节抑制剂的研究进展[J]。生物物理学报,2002,18(1):11。[29]Biscone MJ, Pierson TC, Doms RW。 Opportunities and challenges in targeting HIV entry[J]。 Curr Opin Pharmcol,2002,2 (5):529。[30]Fletcher CV。 Enfuvirtide, a new drug for HIV infection [J]。 Lancet,2003,361:1577。[31]Starr-Spires LD, Collman RG。 HIV-1 entry and entry inhibitors as therapeutic agents [J]。 Clin Lab Med, 2002,22(3): 681。[32]Chan DC, Chutkowski CT, Kim PS。 Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target[J]。Proc Natl Acad Sci USA, 1998,95:15613。[33]Root MJ, Kay MS, Kim PS。 Protein design of an HIV-1 entry inhibitor[J]。 Science ,2001,291:884。[34]Jiang S, Debnath AK。 Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41 [J]。 Biochem Biophys Res Commun ,2000,269:641。[35]姜世勃,张力。人类免疫缺陷病毒包膜糖蛋白gp41核心结构的药物研究[J]。国外医学·微生物学分册,2000,23(4):31。[36]Xavier S, Gerhard H。 Hydrophobicity maps of the N-peptide coiled coil of HIV-1 gp41[J] 。 Biochemistry,2002,41(9) :2956。[37]王峥涛。治疗HIV感染的先导天然化合物[J]。国外医学·药学分册,2001,28(4):227。